Tasly Pharmaceutical Group Co Ltd
Tasly Pharmaceutical Group Co., Ltd researches, develops, manufactures, and sells medicines and related pharmaceuticals in China and internationally. The company provides prescription drugs covering various therapeutic areas, including cardiovascular and cerebrovascular, hepato-biliary-pancreatic, respiratory system, diabetes, tumor immunity, gastrointestinal disease, gynecological, rheumatism, s… Read more
Tasly Pharmaceutical Group Co Ltd (600535) - Total Liabilities
Latest total liabilities as of June 2025: CN¥2.85 Billion CNY
Based on the latest financial reports, Tasly Pharmaceutical Group Co Ltd (600535) has total liabilities worth CN¥2.85 Billion CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tasly Pharmaceutical Group Co Ltd - Total Liabilities Trend (2000–2024)
This chart illustrates how Tasly Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Tasly Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Tasly Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Six Flags Entertainment Corporation
NYSE:FUN
|
USA | $7.03 Billion |
|
Scatec Solar OL
OL:SCATC
|
Norway | Nkr35.51 Billion |
|
Montea C.V.A.
BR:MONT
|
Belgium | €1.35 Billion |
|
Adaptive Biotechnologies Corp
NASDAQ:ADPT
|
USA | $287.74 Million |
|
CGN MINING (VBO.SG)
STU:VBO
|
Germany | €4.71 Billion |
|
TGS ASA
OTCQX:TGSNF
|
USA | $1.90 Billion |
|
Mercari Inc
PINK:MRCIF
|
USA | $444.12 Billion |
|
Yealink Network Technology Corp Ltd
SHE:300628
|
China | CN¥1.11 Billion |
Liability Composition Analysis (2000–2024)
This chart breaks down Tasly Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tasly Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tasly Pharmaceutical Group Co Ltd (2000–2024)
The table below shows the annual total liabilities of Tasly Pharmaceutical Group Co Ltd from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.87 Billion | -28.80% |
| 2023-12-31 | CN¥4.02 Billion | +7.01% |
| 2022-12-31 | CN¥3.76 Billion | +16.50% |
| 2021-12-31 | CN¥3.23 Billion | -21.45% |
| 2020-12-31 | CN¥4.11 Billion | -66.18% |
| 2019-12-31 | CN¥12.15 Billion | -12.99% |
| 2018-12-31 | CN¥13.96 Billion | +11.20% |
| 2017-12-31 | CN¥12.56 Billion | +40.78% |
| 2016-12-31 | CN¥8.92 Billion | +15.75% |
| 2015-12-31 | CN¥7.71 Billion | -1.87% |
| 2014-12-31 | CN¥7.85 Billion | +29.40% |
| 2013-12-31 | CN¥6.07 Billion | +85.06% |
| 2012-12-31 | CN¥3.28 Billion | +14.74% |
| 2011-12-31 | CN¥2.86 Billion | +40.95% |
| 2010-12-31 | CN¥2.03 Billion | +9.36% |
| 2009-12-31 | CN¥1.85 Billion | +36.82% |
| 2008-12-31 | CN¥1.36 Billion | +21.04% |
| 2007-12-31 | CN¥1.12 Billion | -27.29% |
| 2006-12-31 | CN¥1.54 Billion | +29.45% |
| 2005-12-31 | CN¥1.19 Billion | +43.94% |
| 2004-12-31 | CN¥826.42 Million | +43.54% |
| 2003-12-31 | CN¥575.74 Million | +126.94% |
| 2002-12-31 | CN¥253.70 Million | -27.14% |
| 2001-12-31 | CN¥348.19 Million | +31.82% |
| 2000-12-31 | CN¥264.15 Million | -- |